PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER
- 作者: Mikhaylenko D.S1, Perepechin D.V1,2, Grigoryeva M.V1, Zhinzhilo T.A1, Safronova N.Y.1, Efremov G.D1, Sivkov A.V1
-
隶属关系:
- N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation
- Research Centre for Medical Genetics
- 期: 编号 5 (2015)
- 页面: 46-50
- 栏目: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/282236
- ID: 282236
如何引用文章
详细
全文:
作者简介
D. Mikhaylenko
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationPhD Russia, Moscow
D. Perepechin
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian Federation; Research Centre for Medical GeneticsRussia, Moscow
M. Grigoryeva
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationRussia, Moscow
T. Zhinzhilo
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationRussia, Moscow
N. Safronova
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationRussia, Moscow
G. Efremov
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationRussia, Moscow
A. Sivkov
N. Lopatkin Research Institute of Urology - branch of the National Medical Research Radiological Centre at the Ministry of Health of Russian FederationRussia, Moscow
参考
- Злокачественные новообразования в России в 2012 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: ФГБУ «МНИОИ им. П.А. Герцена» Минздрава России, 2014. 250 с.
- Пальцев М.А., Залетаев Д.В. Системы генетических и эпигенетических маркеров в диагностике онкологических заболеваний. М.: Медицина, 2009. 153-187.
- Clarke R.A., Zhao Z., Guo A.Y., Roper K., Teng L., Fang Z.M., Samaratunga H., Lavin M.F., Gardiner RA. New genomic structure for prostate cancer specific gene 3 (PCA3) within BMMC1: implication for prostate cancer detection and progression. PLoS ONE. 2009;4(3):e4995.
- Ефремов Г.Д., Сивков А.В., Михайленко Д.С., Григорьева М.В. Комбинация маркеров РСА3 и TMPRSS2-ERG в ранней диагностике рака предстательной железы (обзор литературы). Экспериментальная и клиническая урология. 2014;3:20-26.
- Killick E., Bancroft E., Kote-Jarai Z., Eeles R. Beyond prostate-specific antigen future biomarkers for the early detection and management of prostate cancer. Clin. Oncol. 2012;24:545-555.
- Kirby R., Fitzpatrick J.M. Optimising repeat prostate biopsy decisions and procedures. BJU Int. 2012;109(12):1750-1754.
- Chevli K.K., Duff M., Walter P., Yu C., Capuder B., Elshafei A., Malczewski S., Kattan M. W., Jones J.S. Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy. J. Urol. 2014;191(6): 1743-1748.
- Capoluongo E., Zambon C.F., Basso D., Boccia S., Rocchetti S., Leoncini E., Palumbo S., Padoan A., Albino G., Todaro A., Prayer-Galetti T., Zattoni F., Zuppi C., Plebani M. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. Clin. Chim. Acta. 2014;429:46-50.
- Pepe P., Fraggetta F., Galia A., Skonieczny G., Aragona F. PCA3 score and prostate cancer diagnosis at repeated saturation biopsy. Which cutoff: 20 or 35? Int. Braz. J. Urol. 2012;38(4):489-495.
- De Luca S., Passera R., Milillo A., Coda R., Randone D.F. Histological chronic prostatitis and high-grade prostate intra-epithelial neoplasia do not influence urinary prostate cancer gene 3 score. BJU Int. 2012;110(11 Pt B):E778-E782.
- De Luca S., Passera R., Cappia S., Bollito E., Randone D.F., Milillo A., Papotti M., Porpiglia F. Fluctuation in prostate cancer gene 3 (PCA3) score in men undergoing first or repeat prostate biopsies. BJU Int. 2014;114:E56-E61.
- Klatte T., Waldert M., de Martino M., Schatzl G., Mannhalter C., Remzi M. Age-specific PCA3 score reference values for diagnosis of prostate cancer. World J. Urol. 2012;30:405-410.
- Chan S.W., Nguyen P.N., Violette P., Brimo F., Taguchi Y., Aprikian A., Chen J.Z. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Med. 2013;2(1):63-75.
- Young A., Palanisamy N., Siddiqui J., Wood D.P., Wei J.T., Chinnaiyan A.M., Kunju L.P., Tomlins S.A. Correlation of urine TMPRSS2:ERG and PCA3 to ERG+ and total prostate cancer burden. Am. J. Clin. Pathol. 2012;138(5):685-696.
- Robert G., Jannink S., Smit F., Aalders T., Hessels D., Cremers R., Mulders P.F., Schalken J.A. Rational basis for the combination of PCA3 and the TMPRSS2:ERG gene fusion for prostate cancer diagnosis. Prostate. 2013;73(2): 113-120.
- Park K., Dalton J.T., Narayanan R., Barbieri C.E., Hancock M.L., Bostwick D.G., Steiner M.S., Rubin M.A. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 2014; 32(3):206-211.
- Leyten G.H., Hessels D., Jannink S.A., Smit F.P., de Jong H., Cornel E.B., de Reijke T.M., Vergunst H., Kil P., Knipscheer B.C., van Oort I.M., Mulders P.F., Hulsbergen-van de Kaa C.A., Schalken J.A. Prospective multicentre evaluation of PCA3 and TMPRSS2:ERG gene fusions as diagnostic and prognostic urinary biomarkers of prostate cancer. Eur Urol. 2014;65(3):534-542.
- Goode R.R., Marshall S.J., Duff M., Chevli E., Chevli K.K. Use of PCA3 in detecting prostate cancer in initial and repeat prostate biopsy patients. Prostate. 2013;73(1):48-53.
- Hansen J., Auprich M., Ahyai S.A. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 2013;63(2):201-209.
- De Luca S., Passera R., Bollito E., Manfredi M., Scarpa R.M., Sottile A., Randone D.F., Porpiglia F. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy. Anticancer Res. 2014;34:7159-7166.
- Merola R., Tomao L., Antenucci A., Sperduti I., Sentinelli S., Masi S., Mandoj C., Orlandi G., Papalia R., Guaglianone S., Costantini M., Cusumano G., Cigliana G., Ascenzi P., Gallucci M., Conti L. PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience. J. Exp. Clin. Cancer Res. 2015;34:15.
- Luo Y., Gou X., Huang P., Mou C. The PCA3 test for guiding repeat biopsy of prostate cancer and its cut-off score: a systematic review and meta-analysis. Asian J. Androl. 2014;16:487-492.
- Wang Y., Liu X.J., Yao X.D. Function of PCA3 in prostate tissue and clinical research progress on developing a PCA3 score. Chin. J. Cancer Res. 2014;26(4):493-500.
- Ng C.F., Yeung R., Chiu P., Lam N.Y., Chow J., Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med. J. 2012;18:459-465.
- Foj L., Mila M., Mengual L., Luque P., Alcaraz A., Jiménez W., Filella X. Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection. Clinica Chimica Acta. 2014;435:53-58.
- Chan S.W., Nguyen P.N., Violette P., Brimo F., Taguchi Y., Aprikian A., Chen J.Z. Early detection of clinically significant prostate cancer at diagnosis: a prospective study using a novel panel of TMPRSS2:ETS fusion gene markers. Cancer Medicine. 2013;2(1):63-75.
- Yao Y.H., Wang H., Li B.G., Tang Y. Evaluation of the TMPRSS2:ERG fusion for the detection of prostate cancer: a systematic review and metaanalysis. Tumor Biol. 2014;35(3):2157-2166.
- Taris M., Irani J., Blanchet P., Multigner L., Cathelineau X., Fromont G. ERG expression in prostate cancer: the prognostic paradox. Prostate. 2014;74:1481-1487.
- Eguchi F.C., Faria E.F., Neto C.S., Longatto-Filho A., Zanardo-Oliveira C., Taboga S.R., Campos S.G. The role of TMPRSS2 :ERG in molecular stratification of Pca and its association with tumor aggressiveness: a study in Brazilian patients. Sci Rep. 2014;35:9597-9602.
- Velarti S., Dimitriadis E., Kontogianni-Katsarou K., Savvani A., Sdrolia E., Pantazi G., Stefanakis S., Trangas T., Pandis N., Petraki K. Detection of TMPRSS2:ERG fusion gene in benign prostatic hyperplasia. Tumor Biol. 2014;35:9597-9602.
- Burdova A., Bouchal J., Tavandzis S., Kolar Z. TMPRSS2-ERG gene fusion in prostate cancer. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 2014;158(4):502-510.
- Udager A.M., Shi Y., Tomlins S.A., Alva A., Siddiqui J., Cao X., Pienta K.J., Jiang H., Chinnaiyan A.M., Mehra R. Frequent discordance between ERG gene rearrangement and ERG protein expression in a rapid autopsy cohort of patients with lethal, metastatic, castration-resistant prostate cancer. Prostate. 2014;74(12):1199-1208.
- Tandefelt D.G., Boormans J., Hermans K., Trapman J. ETS fusion genes in prostate cancer. Endocrine-Related Cancer. 2014;21: R143-R152.
- Park K., Dalton J.T., Narayanan R., Barbieri C.E., Hancock M.L., Bostwick D.G., Steiner M.S., Rubin M.A. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. J. Clin. Oncol. 2013; 32:206-211.
- Altintas D.M., Allioli N., Decaussin M., de Bernard S., Ruffion A., Samarut J., Vlaeminck-Guillem V. Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer. PLoS ONE. 2013;8(6):e66278.
- Hansen J., Auprich M., Ahyai S.A. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur. Urol. 2013;63(2):201-209.
- Perdona S., Bruzzese D., Ferro M., Autorino R., Marino A., Mazzarella C., Perruolo G., Longo M., Spinelli R., Di Lorenzo G., Oliva A., De Sio M., Damiano R., Altieri V., Terracciano D. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. 2013;73(3):227-235.
- Sartori D.A., Chan D.W. Biomarkers in prostate cancer: what’s new? Curr. Opin. Oncol. 2014;26(3):259-264.